Volume Alert - BSX 13.40 Boston Scientific Corp $BSX Hit a high today of 13.42 Closing the day 10:30 at 13.40 +0.04 +0.30% With a day low of 13.28 and a total volume of 2,431,996.
BSX Recent Posts: http://investorshangout.com/Boston-Scientific...BSX-50374/
BSX Boston Scientific Corp Recent Headline News
First U.S. Procedures Completed With The Symphion(TM) Hysteroscopic Tissue Removal System
PR Newswire - Mon Nov 17, 8:00AM CST
Boston Scientific Corporation (NYSE: BSX) announces the completion of the first U.S. procedures performed with the Symphion System, designed for the hysteroscopic removal of interuterine fibroids and polyps. The all-in-one Symphion System combines a self-contained, recirculating fluid management system, direct intrauterine pressure monitoring and bladeless bipolar RF plasma resection to remove uterine tissue. Hysteroscopic removal of symptomatic fibroids and polyps is a minimally invasive surgical technique and intended to be less traumatic to the patient.
BSX: 13.39 (+0.03)
Insider Trading Alerts for Tesla, Globalstar, Boston Scientific, Apple, Yahoo, and Twitter
PR Newswire - Mon Nov 17, 7:45AM CST
Pennystocksinsiders.com (PSI) released FREE insider trading reports for US market investors to track the following active stocks and penny stocks: Tesla (NASDAQ:TSLA), Globalstar (NYSEMKT:GSAT), Boston Scientific (NYSE:BSX), Apple (NASDAQ:AAPL), Yahoo! (NASDAQ:YHOO), and Plug Power (NASDAQ
LUG).
BSX: 13.39 (+0.03), YHOO: 51.16 (-0.59), TSLA: 253.71 (-4.97), PLUG: 3.78 (+0.06), TWTR: 40.61 (-1.24), AAPL: 113.56 (-0.62), GSAT: 2.83 (-0.14)
Jury Finds for Four Women in Multi-Million-Dollar Boston Scientific Bellwether Cases, Parker Waichman LLP Comments
PRWeb - Fri Nov 14, 8:30PM CST
Parker Waichman LLP, a national law firm that has long been dedicated to protecting the rights of victims who have been injured by medical devices, comments on a case in which a Florida federal jury found in favor of four women who allege they suffered injuries as a result of Boston Scientific Corp.'s pelvic mesh implant device, the Pinnacle Pelvic Floor Repair Kit. The jury awarded the four women with $26.7 million. The case is Amal Eghnayem et al. v. Boston Scientific Corp., case number 1:14-cv-24061, in the U.S. District Court for the Southern District of Florida.
BSX: 13.39 (+0.03)
Boston Sci loses first federal case over vaginal mesh product
Seeking Alpha - at Seeking Alpha - Fri Nov 14, 9:08AM CST
BSX: 13.38 (+0.02)
Subcutaneous Implantable Defibrillator Receives Favorable Coding And Payment Designations For 2015
PR Newswire - Thu Nov 13, 4:07PM CST
Boston Scientific Corporation (NYSE: BSX) announced that its subcutaneous implantable defibrillator (S-ICD System(TM)) will have designated Current Procedural Terminology (CPT®) Category I codes by the American Medical Association (AMA), effective January 1, 2015. The AMA CPT coding system provides U.S. physicians and hospitals with a uniform process for coding medical services. By definition, the CPT I category includes procedures that are widely performed and consistent with contemporary medical practice.
BSX: 13.38 (+0.02)
Insider Trading Alert - UIS, BSX And OLED Traded By Insiders
at The Street - Thu Nov 13, 10:30AM CST
Stocks with insider trader activity include UIS, BSX and OLED
BSX: 13.38 (+0.02), OLED: 26.92 (-0.63), UIS: 27.17 (-0.62)
Pegasus Legal Funding Foresees an Increase in Transvaginal Mesh Lawsuits Following Spotlight on Recent $73MM Jury Award
PR Newswire - Thu Nov 13, 6:34AM CST
Pegasus Legal Funding, LLC, announced today that they plan to prioritize their pre-settlement funding claims on transvaginal mesh cases based on the recent upswing in lawsuits being filed against Boston Scientific Corp. and others. Earlier this month Bloomberg News announced that a $73 million verdict was awarded to a Texas plaintiff in a transvaginal mesh lawsuit filed against Boston Scientific, however, that award has since been cut to $11 million due to the fact that Texas caps punitive damages at no more than two times a plaintiff's economic losses, plus up to $750,000 in non-economic losses.
BSX: 13.38 (+0.02)
Neurostimulation Devices Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Competitive Scenario And Forecasts, 2012 To 2020
M2 - Thu Nov 13, 2:52AM CST
Industry Insights
BSX: 13.38 (+0.02), MDT: 69.26 (+0.31), CYBX: 53.00 (+0.28)
Meridian Bioscience (VIVO) Misses Q4 Earnings, Revenues - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Nov 12, 9:20AM CST
Meridian Bioscience Inc. (VIVO) reported fourth-quarter fiscal 2014 earnings of 20 cents per share, which missed the Zacks Consensus Estimate by a couple of cents
BSX: 13.38 (+0.02), VIVO: 16.10 (-0.09), ABAX: 54.87 (+0.07), OSUR: 8.89 (+0.12)
Novel Drug Delivery System (NDDS) in Cancer Therapy Market - Global Industry Analysis to 2020 for the $15 Billion Market
M2 - Wed Nov 12, 3:22AM CST
Research and Markets (http://www.researchandmarkets.com/research/ws3rns/ndds_in_cancer) has announced the addition of the "NDDS in Cancer Therapy Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2014 - 2020" report to their offering. The global market for NDDS in cancer therapy was valued at USD 3,655.3 million in 2013 and is expected to reach USD 15,984.2 million in 2020, growing at a CAGR of 23.7% during the forecast period from 2014 to 2020 The world is witnessing a continuous rise in the incidence of various types of cancer. Clinical benefits of embolic agents and nanoparticles over other therapy and drug delivery systems; technological advances leading to the development of new and innovative therapy; and expanding therapeutic indications of existing NDDS are some of the major factors expected to drive growth of the global NDDS in cancer therapy market during the forecast period from 2014 to 2020. On the other hand, factors such as high treatment cost associated with NDDS, strict regulatory pathways and cost associated with new product development may restrict market growth to some extent. One of the major opportunities in this market is nano-enabled drug delivery systems as this segment has been anticipated to grow at the highest CAGR of 24.7% during the forecast period. Embolization particles, liquid embolics and nanoparticles as drug delivery systems altogether comprise the global market for NDDS in cancer therapy. PVA particles, microspheres, drug eluting beads (DEB) and selective internal radiation therapy (SIRT) are the major products under the embolization particles market segment, while Onyx LES and TRUFILL nBCA LES are the two major liquid embolic system brands. The liquid embolics market segment is expected to grow at a CAGR of 4.9% during the forecast period from 2014 to 2020. Nanoparticles in novel drug delivery systems have emerged as a promising technology to treat patients suffering from various types of cancer. The market for nanoparticles segment was valued at USD 3,307.7 million in 2013 with the largest revenue share in the overall NDDS in cancer therapy market. Over the past two decades, many nanoparticles such as Doxil (doxorubicin), Megace ES (megestrol acetate), Abraxane (paclitaxel), Myocet (doxorubicin), DepoCyt (liposomal cytarabine), and DaunoXome (daunorubicin citrate) have been approved as drug delivery systems for cancer therapy. NDDS in Cancer Therapy Market, by Technology Embolization Particles Current Technologies - Drug Eluting Beads - Others (PVA particles, microspheres, gelatin-based) Emerging Technologies - Selective Internal Radiation Therapy (SIRT) - TheraSphere - SIR-Spheres - Holmium-based Microspheres Liquid Embolics - Onyx (LES and HD-500) - TRUFILL nBCA LES Nanoparticles Key Topics Covered: Chapter 1 Preface Chapter 2 Executive Summary Chapter 3 Market Overview Chapter 4 Global Embolization Particles Market Revenue, by Type Chapter 5 Global Liquid Embolics Market Revenue, by Brand Chapter 6 Global Nanoparticles Market Revenue Chapter 7 Global NDDS in Cancer Therapy Market, by Geography Chapter 8 Recommendations Companies Mentioned - Advanced Medical Isotope Corporation - BTG plc - Bind Therapeutics - Boston Scientific Corporation - CeloNova BioSciences - Cook Medical - Cospheric LLC - Covidien - Eckert & Ziegler BEBIG - EmboMedics - Terumo Medical Corporation. - Kobo Products - Merit Medical Systems - Mo-Sci Corporation - Nanobiotix - Polysciences - Sirtex Medical For more information visit http://www.researchandmarkets.com/research/ws..._in_cancer
BSX: 13.38 (+0.02), MMSI: 14.93 (-0.03)
Omnicell Reports Mixed Q3, Positive on Surgichem Buyout - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Nov 11, 2:00PM CST
On Nov 6, 2014, we issued an updated research report on Omnicell Inc. (OMCL).
BSX: 13.38 (+0.02), ICUI: 86.72 (+1.01), ABAX: 54.87 (+0.07), OMCL: 32.20 (-0.06)
Boston Scientific Shows Strength on Core Market Stabilization - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Nov 11, 1:50PM CST
On Nov 7, 2014, we issued an updated research report on leading medical devices company Boston Scientific Corporation (BSX).
BSX: 13.38 (+0.02), ICUI: 86.72 (+1.01), BCR: 164.42 (+0.38), ABAX: 54.87 (+0.07)
Nevro - I Remain Cautious After A Successful Debut For This Pain Relief Company
The Value Investor - at Seeking Alpha - Tue Nov 11, 7:43AM CST
BSX: 13.38 (+0.02), NVRO: 26.72 (+1.18)
U.S. Market for Peripheral Vascular Devices and Accessories Executive Summary: By 2020, the U.S. market for peripheral vascular devices will be worth over $6 billion
M2 - Tue Nov 11, 6:43AM CST
Research and Markets (http://www.researchandmarkets.com/research/3rwwd3/u_s_market_for) has announced the addition of the "U.S. Market for Peripheral Vascular Devices and Accessories (Executive Summary)" report to their offering. The peripheral vascular device market includes stents, percutaneous transluminal angioplasty (PTA) balloon catheters, atherectomy devices, chronic total occlusion devices, stent grafts, surgical grafts, arteriovenous (AV) access thrombectomy devices, inferior vena cava filters, catheters, guidewires, introducer sheaths, vascular closure devices and transcatheter embolization devices. These devices can be used for treating either coronary arterial or peripheral arterial disease (PAD), but only those devices used for peripheral procedures are included in this report. Older individuals and those who are obese have a higher risk of developing PAD. As result of a general increase in peripheral procedures and the development of new lower-limb treatments, the market for products such as stents and stent grafts will grow rapidly in the U.S. over the forecast period. Peripheral artery disease (PAD) remains a significantly under treated condition in the U.S and PAD is the leading cause of leg amputation. These factors will continue to drive growth in the peripheral vascular device market. In particular, the peripheral stent market is projected to grow over the forecast period. However, intense competition has led to price erosion and market penetration has moderated this once high growth segment. The launch of new technologies, including drug-eluting stents, will generate marginal revenues and only one company has sought FDA approval. In contrast, significant investments and acquisitions have taken place in the efforts of bringing the first drug-eluting balloon to the market, with Medtronic and C. R. Bard in a tight race to gain approval. Scope - Competitor Analysis - Identified Strategic Opportunities - Market Overview by Segment - Trend Analysis by Segment - Market Drivers & Limiters - Mergers & Acquisitions - Customer Feedback and Market Monitoring Main Segments Included: - Peripheral Vascular Stent Market - PTA Balloon Catheter Market - Atherectomy Device Market - Chronic Total Occlusion (CTO) Device Market - Embolic Protection Device Market - Stent Graft Market - Surgical Graft Market - AV Access Thrombectomy Device Market - Inferior Vena Cava Filter Market - Diagnostic and Interventional Catheter Market - Diagnostic and Interventional Guidewire Market - Introducer Sheath Market - Vascular Closure Device Market - Transcatheter Embolization Device Market Companies Mentioned - ALN International Inc. - Abbott Laboratories - AccessClosure - AngioDynamics - AngioScore - Angiotech - Argon Medical - Arstasis - Artegraft - Asahi Intecc USA - Atrax - Atrium Medical - B. Braun - Boston Scientific - C. R. Bard - Cardiovascular Systems Inc - Cardiva CeloNova Biosciences - Cook Medical - Cordis - Covidien - Endologix - IDEV Technologies - LeMaitre Vascular - MEDRAD - Maquet - Marine Polymer Technologies - Medtronic - Morris Innovative - Penumbra - Pfizer For more information visit http://www.researchandmarkets.com/research/3r...market_for About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
BSX: 13.39 (+0.03), ABT: 43.72 (-0.09), MDT: 69.24 (+0.29), CSII: 28.34 (-0.04), LMAT: 7.15 (+0.05)
Walgreens Hits the Rock with Court's Ruling on CFO Lawsuit - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Nov 10, 2:30PM CST
The controversy surrounding an inflated fiscal 2016 earnings forecast continues for leading drugstore chain Walgreen Co. (WAG).
BSX: 13.39 (+0.03), ICUI: 86.72 (+1.01), ABAX: 54.87 (+0.07), WAG: 66.48 (-0.45)
Medtronic launches MRI-compatible ICD system in Japan
Seeking Alpha - at Seeking Alpha - Mon Nov 10, 9:49AM CST
BSX: 13.39 (+0.03), MDT: 69.24 (+0.29), STJ: 65.05 (+0.06)
Could This Obamacare Tax Be Repealed?
Sean Williams, The Motley Fool - Motley Fool - Sun Nov 09, 7:18AM CST
Source: White House on Flickr. With the midterm elections now in the rear-view mirror, Americans can begin speculating about the policies that will come out of Washington over the next two years. Personally, I can't say I'm a huge fan of the...
ZMH: 110.54 (+0.42), BSX: 13.39 (+0.03), MDT: 69.24 (+0.29), NUVA: 44.65 (+0.87)
BioScrip (BIOS) Q3 Loss Wider than Expected, Revenues Top - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Nov 07, 2:10PM CST
BioScrip, Inc. (BIOS) recently declared its third-quarter 2014 results.
BSX: 13.39 (+0.03), ICUI: 86.72 (+1.01), ABAX: 54.87 (+0.07), BIOS: 5.73 (-0.18)
Boston Scientific (BSX) Breaks Through Support at $13.31
Comtex SmarTrend(R) - Fri Nov 07, 12:25PM CST
Boston Scientific (NYSE:BSX) has opened bearishly below the pivot of $13.37 today and has reached the first level of support at $13.31. Analysts will be watching for a cross of the next downside pivot targets of $13.27 and $13.17.
BSX: 13.39 (+0.03)
Omnicell Earnings Hit by High Tax, User Addition Aids Sales - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Nov 07, 11:27AM CST
On Nov 7, 2014, we issued an updated research report on Omnicell Inc. (OMCL).
BSX: 13.39 (+0.03), ICUI: 86.72 (+1.01), ABAX: 54.87 (+0.07), OMCL: 32.20 (-0.06)
BSX Recent Posts: http://investorshangout.com/Boston-Scientific...BSX-50374/
BSX Boston Scientific Corp Recent Headline News
First U.S. Procedures Completed With The Symphion(TM) Hysteroscopic Tissue Removal System
PR Newswire - Mon Nov 17, 8:00AM CST
Boston Scientific Corporation (NYSE: BSX) announces the completion of the first U.S. procedures performed with the Symphion System, designed for the hysteroscopic removal of interuterine fibroids and polyps. The all-in-one Symphion System combines a self-contained, recirculating fluid management system, direct intrauterine pressure monitoring and bladeless bipolar RF plasma resection to remove uterine tissue. Hysteroscopic removal of symptomatic fibroids and polyps is a minimally invasive surgical technique and intended to be less traumatic to the patient.
BSX: 13.39 (+0.03)
Insider Trading Alerts for Tesla, Globalstar, Boston Scientific, Apple, Yahoo, and Twitter
PR Newswire - Mon Nov 17, 7:45AM CST
Pennystocksinsiders.com (PSI) released FREE insider trading reports for US market investors to track the following active stocks and penny stocks: Tesla (NASDAQ:TSLA), Globalstar (NYSEMKT:GSAT), Boston Scientific (NYSE:BSX), Apple (NASDAQ:AAPL), Yahoo! (NASDAQ:YHOO), and Plug Power (NASDAQ
LUG). BSX: 13.39 (+0.03), YHOO: 51.16 (-0.59), TSLA: 253.71 (-4.97), PLUG: 3.78 (+0.06), TWTR: 40.61 (-1.24), AAPL: 113.56 (-0.62), GSAT: 2.83 (-0.14)
Jury Finds for Four Women in Multi-Million-Dollar Boston Scientific Bellwether Cases, Parker Waichman LLP Comments
PRWeb - Fri Nov 14, 8:30PM CST
Parker Waichman LLP, a national law firm that has long been dedicated to protecting the rights of victims who have been injured by medical devices, comments on a case in which a Florida federal jury found in favor of four women who allege they suffered injuries as a result of Boston Scientific Corp.'s pelvic mesh implant device, the Pinnacle Pelvic Floor Repair Kit. The jury awarded the four women with $26.7 million. The case is Amal Eghnayem et al. v. Boston Scientific Corp., case number 1:14-cv-24061, in the U.S. District Court for the Southern District of Florida.
BSX: 13.39 (+0.03)
Boston Sci loses first federal case over vaginal mesh product
Seeking Alpha - at Seeking Alpha - Fri Nov 14, 9:08AM CST
BSX: 13.38 (+0.02)
Subcutaneous Implantable Defibrillator Receives Favorable Coding And Payment Designations For 2015
PR Newswire - Thu Nov 13, 4:07PM CST
Boston Scientific Corporation (NYSE: BSX) announced that its subcutaneous implantable defibrillator (S-ICD System(TM)) will have designated Current Procedural Terminology (CPT®) Category I codes by the American Medical Association (AMA), effective January 1, 2015. The AMA CPT coding system provides U.S. physicians and hospitals with a uniform process for coding medical services. By definition, the CPT I category includes procedures that are widely performed and consistent with contemporary medical practice.
BSX: 13.38 (+0.02)
Insider Trading Alert - UIS, BSX And OLED Traded By Insiders
at The Street - Thu Nov 13, 10:30AM CST
Stocks with insider trader activity include UIS, BSX and OLED
BSX: 13.38 (+0.02), OLED: 26.92 (-0.63), UIS: 27.17 (-0.62)
Pegasus Legal Funding Foresees an Increase in Transvaginal Mesh Lawsuits Following Spotlight on Recent $73MM Jury Award
PR Newswire - Thu Nov 13, 6:34AM CST
Pegasus Legal Funding, LLC, announced today that they plan to prioritize their pre-settlement funding claims on transvaginal mesh cases based on the recent upswing in lawsuits being filed against Boston Scientific Corp. and others. Earlier this month Bloomberg News announced that a $73 million verdict was awarded to a Texas plaintiff in a transvaginal mesh lawsuit filed against Boston Scientific, however, that award has since been cut to $11 million due to the fact that Texas caps punitive damages at no more than two times a plaintiff's economic losses, plus up to $750,000 in non-economic losses.
BSX: 13.38 (+0.02)
Neurostimulation Devices Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Competitive Scenario And Forecasts, 2012 To 2020
M2 - Thu Nov 13, 2:52AM CST
Industry Insights
BSX: 13.38 (+0.02), MDT: 69.26 (+0.31), CYBX: 53.00 (+0.28)
Meridian Bioscience (VIVO) Misses Q4 Earnings, Revenues - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Nov 12, 9:20AM CST
Meridian Bioscience Inc. (VIVO) reported fourth-quarter fiscal 2014 earnings of 20 cents per share, which missed the Zacks Consensus Estimate by a couple of cents
BSX: 13.38 (+0.02), VIVO: 16.10 (-0.09), ABAX: 54.87 (+0.07), OSUR: 8.89 (+0.12)
Novel Drug Delivery System (NDDS) in Cancer Therapy Market - Global Industry Analysis to 2020 for the $15 Billion Market
M2 - Wed Nov 12, 3:22AM CST
Research and Markets (http://www.researchandmarkets.com/research/ws3rns/ndds_in_cancer) has announced the addition of the "NDDS in Cancer Therapy Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2014 - 2020" report to their offering. The global market for NDDS in cancer therapy was valued at USD 3,655.3 million in 2013 and is expected to reach USD 15,984.2 million in 2020, growing at a CAGR of 23.7% during the forecast period from 2014 to 2020 The world is witnessing a continuous rise in the incidence of various types of cancer. Clinical benefits of embolic agents and nanoparticles over other therapy and drug delivery systems; technological advances leading to the development of new and innovative therapy; and expanding therapeutic indications of existing NDDS are some of the major factors expected to drive growth of the global NDDS in cancer therapy market during the forecast period from 2014 to 2020. On the other hand, factors such as high treatment cost associated with NDDS, strict regulatory pathways and cost associated with new product development may restrict market growth to some extent. One of the major opportunities in this market is nano-enabled drug delivery systems as this segment has been anticipated to grow at the highest CAGR of 24.7% during the forecast period. Embolization particles, liquid embolics and nanoparticles as drug delivery systems altogether comprise the global market for NDDS in cancer therapy. PVA particles, microspheres, drug eluting beads (DEB) and selective internal radiation therapy (SIRT) are the major products under the embolization particles market segment, while Onyx LES and TRUFILL nBCA LES are the two major liquid embolic system brands. The liquid embolics market segment is expected to grow at a CAGR of 4.9% during the forecast period from 2014 to 2020. Nanoparticles in novel drug delivery systems have emerged as a promising technology to treat patients suffering from various types of cancer. The market for nanoparticles segment was valued at USD 3,307.7 million in 2013 with the largest revenue share in the overall NDDS in cancer therapy market. Over the past two decades, many nanoparticles such as Doxil (doxorubicin), Megace ES (megestrol acetate), Abraxane (paclitaxel), Myocet (doxorubicin), DepoCyt (liposomal cytarabine), and DaunoXome (daunorubicin citrate) have been approved as drug delivery systems for cancer therapy. NDDS in Cancer Therapy Market, by Technology Embolization Particles Current Technologies - Drug Eluting Beads - Others (PVA particles, microspheres, gelatin-based) Emerging Technologies - Selective Internal Radiation Therapy (SIRT) - TheraSphere - SIR-Spheres - Holmium-based Microspheres Liquid Embolics - Onyx (LES and HD-500) - TRUFILL nBCA LES Nanoparticles Key Topics Covered: Chapter 1 Preface Chapter 2 Executive Summary Chapter 3 Market Overview Chapter 4 Global Embolization Particles Market Revenue, by Type Chapter 5 Global Liquid Embolics Market Revenue, by Brand Chapter 6 Global Nanoparticles Market Revenue Chapter 7 Global NDDS in Cancer Therapy Market, by Geography Chapter 8 Recommendations Companies Mentioned - Advanced Medical Isotope Corporation - BTG plc - Bind Therapeutics - Boston Scientific Corporation - CeloNova BioSciences - Cook Medical - Cospheric LLC - Covidien - Eckert & Ziegler BEBIG - EmboMedics - Terumo Medical Corporation. - Kobo Products - Merit Medical Systems - Mo-Sci Corporation - Nanobiotix - Polysciences - Sirtex Medical For more information visit http://www.researchandmarkets.com/research/ws..._in_cancer
BSX: 13.38 (+0.02), MMSI: 14.93 (-0.03)
Omnicell Reports Mixed Q3, Positive on Surgichem Buyout - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Nov 11, 2:00PM CST
On Nov 6, 2014, we issued an updated research report on Omnicell Inc. (OMCL).
BSX: 13.38 (+0.02), ICUI: 86.72 (+1.01), ABAX: 54.87 (+0.07), OMCL: 32.20 (-0.06)
Boston Scientific Shows Strength on Core Market Stabilization - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Nov 11, 1:50PM CST
On Nov 7, 2014, we issued an updated research report on leading medical devices company Boston Scientific Corporation (BSX).
BSX: 13.38 (+0.02), ICUI: 86.72 (+1.01), BCR: 164.42 (+0.38), ABAX: 54.87 (+0.07)
Nevro - I Remain Cautious After A Successful Debut For This Pain Relief Company
The Value Investor - at Seeking Alpha - Tue Nov 11, 7:43AM CST
BSX: 13.38 (+0.02), NVRO: 26.72 (+1.18)
U.S. Market for Peripheral Vascular Devices and Accessories Executive Summary: By 2020, the U.S. market for peripheral vascular devices will be worth over $6 billion
M2 - Tue Nov 11, 6:43AM CST
Research and Markets (http://www.researchandmarkets.com/research/3rwwd3/u_s_market_for) has announced the addition of the "U.S. Market for Peripheral Vascular Devices and Accessories (Executive Summary)" report to their offering. The peripheral vascular device market includes stents, percutaneous transluminal angioplasty (PTA) balloon catheters, atherectomy devices, chronic total occlusion devices, stent grafts, surgical grafts, arteriovenous (AV) access thrombectomy devices, inferior vena cava filters, catheters, guidewires, introducer sheaths, vascular closure devices and transcatheter embolization devices. These devices can be used for treating either coronary arterial or peripheral arterial disease (PAD), but only those devices used for peripheral procedures are included in this report. Older individuals and those who are obese have a higher risk of developing PAD. As result of a general increase in peripheral procedures and the development of new lower-limb treatments, the market for products such as stents and stent grafts will grow rapidly in the U.S. over the forecast period. Peripheral artery disease (PAD) remains a significantly under treated condition in the U.S and PAD is the leading cause of leg amputation. These factors will continue to drive growth in the peripheral vascular device market. In particular, the peripheral stent market is projected to grow over the forecast period. However, intense competition has led to price erosion and market penetration has moderated this once high growth segment. The launch of new technologies, including drug-eluting stents, will generate marginal revenues and only one company has sought FDA approval. In contrast, significant investments and acquisitions have taken place in the efforts of bringing the first drug-eluting balloon to the market, with Medtronic and C. R. Bard in a tight race to gain approval. Scope - Competitor Analysis - Identified Strategic Opportunities - Market Overview by Segment - Trend Analysis by Segment - Market Drivers & Limiters - Mergers & Acquisitions - Customer Feedback and Market Monitoring Main Segments Included: - Peripheral Vascular Stent Market - PTA Balloon Catheter Market - Atherectomy Device Market - Chronic Total Occlusion (CTO) Device Market - Embolic Protection Device Market - Stent Graft Market - Surgical Graft Market - AV Access Thrombectomy Device Market - Inferior Vena Cava Filter Market - Diagnostic and Interventional Catheter Market - Diagnostic and Interventional Guidewire Market - Introducer Sheath Market - Vascular Closure Device Market - Transcatheter Embolization Device Market Companies Mentioned - ALN International Inc. - Abbott Laboratories - AccessClosure - AngioDynamics - AngioScore - Angiotech - Argon Medical - Arstasis - Artegraft - Asahi Intecc USA - Atrax - Atrium Medical - B. Braun - Boston Scientific - C. R. Bard - Cardiovascular Systems Inc - Cardiva CeloNova Biosciences - Cook Medical - Cordis - Covidien - Endologix - IDEV Technologies - LeMaitre Vascular - MEDRAD - Maquet - Marine Polymer Technologies - Medtronic - Morris Innovative - Penumbra - Pfizer For more information visit http://www.researchandmarkets.com/research/3r...market_for About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
BSX: 13.39 (+0.03), ABT: 43.72 (-0.09), MDT: 69.24 (+0.29), CSII: 28.34 (-0.04), LMAT: 7.15 (+0.05)
Walgreens Hits the Rock with Court's Ruling on CFO Lawsuit - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Nov 10, 2:30PM CST
The controversy surrounding an inflated fiscal 2016 earnings forecast continues for leading drugstore chain Walgreen Co. (WAG).
BSX: 13.39 (+0.03), ICUI: 86.72 (+1.01), ABAX: 54.87 (+0.07), WAG: 66.48 (-0.45)
Medtronic launches MRI-compatible ICD system in Japan
Seeking Alpha - at Seeking Alpha - Mon Nov 10, 9:49AM CST
BSX: 13.39 (+0.03), MDT: 69.24 (+0.29), STJ: 65.05 (+0.06)
Could This Obamacare Tax Be Repealed?
Sean Williams, The Motley Fool - Motley Fool - Sun Nov 09, 7:18AM CST
Source: White House on Flickr. With the midterm elections now in the rear-view mirror, Americans can begin speculating about the policies that will come out of Washington over the next two years. Personally, I can't say I'm a huge fan of the...
ZMH: 110.54 (+0.42), BSX: 13.39 (+0.03), MDT: 69.24 (+0.29), NUVA: 44.65 (+0.87)
BioScrip (BIOS) Q3 Loss Wider than Expected, Revenues Top - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Nov 07, 2:10PM CST
BioScrip, Inc. (BIOS) recently declared its third-quarter 2014 results.
BSX: 13.39 (+0.03), ICUI: 86.72 (+1.01), ABAX: 54.87 (+0.07), BIOS: 5.73 (-0.18)
Boston Scientific (BSX) Breaks Through Support at $13.31
Comtex SmarTrend(R) - Fri Nov 07, 12:25PM CST
Boston Scientific (NYSE:BSX) has opened bearishly below the pivot of $13.37 today and has reached the first level of support at $13.31. Analysts will be watching for a cross of the next downside pivot targets of $13.27 and $13.17.
BSX: 13.39 (+0.03)
Omnicell Earnings Hit by High Tax, User Addition Aids Sales - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Nov 07, 11:27AM CST
On Nov 7, 2014, we issued an updated research report on Omnicell Inc. (OMCL).
BSX: 13.39 (+0.03), ICUI: 86.72 (+1.01), ABAX: 54.87 (+0.07), OMCL: 32.20 (-0.06)
